Precision Medicine Initiative Aims High But Must Surmount Technical, Practical Hurdles
Executive Summary
White House proposal for a longitudinal cohort encompassing one million people seeks to leverage ongoing studies. But bringing all that data together under one roof, and ensuring it is useful and participants’ privacy is adequately protected, promises to be a significant task.
You may also be interested in...
‘Precision Medicine’ Gets R&D Funding Push In President’s Speech
President Obama highlights potential for personalized medicine in his State of the Union address and will seek a “major increase” in research and development funding.
Lung-MAP Patient Screening Should Translate To Cost-Savings
Sponsors say the large number of biomarkers that will be searched for in candidates for the lung cancer trial should allow researchers to find patients much faster, and will offer cost-savings over traditional drug development.
Diabetes Drugs: US FDA Proposes Hypoglycemia Efficacy Endpoints, With Limits
Reduction in the risk of hypoglycemia level 2 and 3 events, along with either a reduction or maintenance of an acceptable hemoglobin A1C, is a clinically relevant efficacy endpoint for drug development in Types 1 and 2 diabetes, FDA states in new draft guidance.